VBL Therapeutics to Present Positive Phase 1/2 Data for VB-111 in Recurrent Platinum-Resistant Mullerian Cancer at ASCO Annual Meeting

TEL AVIV, Israel, May 13, 2015  -- VBL Therapeutics (VBLT), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that principal investigator, Richard Penson, M.D., M.R.C.P., will present interim data from the ongoing Phase 1/2 clinical trial of lead product candidate, VB-111, for the treatment of platinum-resistant Mullerian cancer, in a poster presentation on Saturday, May 30, 2015 at the American Society for Clinical Oncology (ASCO) 2015 Annual Meeting. The reported data will include results in patients with recurrent platinum-resistant Mullerian cancer treated with multiple doses of VB-111 and weekly paclitaxel.

Fibrocell Receives Rare Pediatric Disease Designation From FDA for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Gene-Therapy Drug Candidate is Potential First-in-Class Treatment for RDEB -- A Rare, Congenital, Devastating Skin Disease

EXTON, Pa., May 12, 2015  -- Fibrocell Science, Inc., (FCSC), an autologous cell and gene therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for Fibrocell's lead orphan gene-therapy drug candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The rare pediatric disease designation augments the Orphan Drug designation granted by the FDA and announced by Fibrocell in June 2014 for FCX-007 to treat dystrophic epidermolysis bullosa (DEB), which includes RDEB.

Pain Therapeutics Announces Positive Top-Line Results From Human Abuse Potential Study With REMOXY

REMOXY Meets Both Primary Endpoints with Statistical Significance (p<0.0001)

AUSTIN, Texas, May 12, 2015  -- Pain Therapeutics, Inc., (PTIE) today announced top-line results of an FDA Category 3 Human Abuse Potential Study with REMOXY Extended-Release Capsules CII, its lead drug candidate that is specifically designed to discourage certain common methods of drug tampering and misuse. This study demonstrated with statistical significance (p<0.0001) that both intact and chewed REMOXY were less "liked" than immediate-release oxycodone on the two primary endpoints, Drug Liking and Drug High. The Abuse Potential study was conducted in non-dependent, recreational opioid users, as recommended by FDA guidelines.

Can-Fite's Phase II Liver Cancer Trial Approved in Europe

First patient dosed in Europe
The global market for liver cancer is projected to exceed $2 billion in 2015

PETACH TIKVA, Israel, May 11, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. Shortly after receiving approval, the first patient in Europe was dosed.